Patient-oriented Research: Colon CA & Cancer Immunology

以患者为导向的研究：Colon CA

• 批准号: 7586771
• 负责人: RANDALL F HOLCOMBE
• 金额: $ 14.96万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-19 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7586771
• 关键词: Award; Biological Assay; Cancer Immunology Science; Clinical Research; Clinical Trials; Colon; Colon Carcinoma; Colorectal Cancer; Contracts; Correlative Study; Data; Dendritic Cells; Development; Diagnosis; Disease; Documentation; Event; Goals; Grapes; Hand; Hematology; Immune; Immune response; Immune system; Immunization; Immunologics; In Vitro; Inflammatory Bowel Diseases; Instruction; Interferons; Laboratories; Life Expectancy; Malignant Neoplasms; Measures; Mentors; Metastatic/Recurrent; Midcareer Investigator Award in Patient-Oriented Research; Monitor; Patients; Pilot Projects; Preventive; Research Ethics Committees; Resveratrol; Role; Signal Pathway; Skin; Therapeutic; Therapeutic Clinical Trial; Time; Translational Research; Work; Writing; base; chemotherapy; design; experience; high risk; improved; malignant stomach neoplasm; oncology; patient oriented research; peripheral blood; response; treatment strategy; tumor

This application is submitted as a competitive renewal of a midcareer investigator award in patient-oriented research (K24CA82450). The PI is Randall F. Holcombe, MD. This application details the experience, qualifications and short- and long-term patient-oriented research plans of Dr. Holcombe, as well as reviews progress during the period of support under the current award. Details about current and planned patient- oriented research is provided. These studies are focused on patient-oriented research in colon cancer and include studies related to the Wnt signaling pathway, elucidation of immunologic events in conjunction with administration of chemotherapy for colon cancer and definition of the mechanisms and potential therapeutic and cancer preventive effects of resveratrol, a naturally occuring compound found in the skin of grapes. Patients with inflammatory bowel disease, having or at high risk for colon cancer, are also studied. An additional clinical trial with laboratory correlative studies, originally designed and written by a mentee hematology-oncology fellow of Dr. Holcombe's involves the treatment of patients with gastric cancer. Mentoring activity over the past 5 years and mentoring plans for the next 5 years are described. The accomplishments of mentees are outlined as are their current activities, espeicially as related to ongoing participation in patient-oriented research. Ongoing mentoring plans include formal coursework, basic/translational research experiences, instruction in the development and implementation of clinical research trials, and hands-on experiences in clinical research. The original goals and objectives of the current award are reviewed and the extent to which these have been achieved is delineated. Documentation of institutional support and justification of the need for continued support through the K24 mechanism is provided.

本申请是作为一个竞争性的更新职业生涯中期研究者奖在以病人为导向的 研究（K24 CA 82450）。PI是Randall F。马里兰州霍尔科姆这个应用程序详细介绍了经验， Holcombe博士的资格和短期和长期以患者为导向的研究计划，以及审查 在当前奖项的支持期间取得的进展。关于当前和计划患者的详细信息- 进行了定向研究。这些研究主要集中在结肠癌的患者导向研究， 包括与Wnt信号通路相关的研究，结合免疫学事件的阐明， 结肠癌化疗的管理和机制的定义和潜在的治疗 白藜芦醇是一种天然存在于葡萄皮中的化合物。 还研究了患有炎症性肠病、患有结肠癌或处于结肠癌高风险中的患者。一个 附加临床试验与实验室相关研究，最初由学员设计和编写 Holcombe博士的血液肿瘤学研究员涉及胃癌患者的治疗。 介绍了过去5年的指导活动和未来5年的指导计划。的 概述了学员的成就，以及他们目前的活动，特别是与正在进行的 参与以病人为导向的研究。正在进行的辅导计划包括正式的课程， 基础/转化研究经验，临床开发和实施指导 研究试验和临床研究的实践经验。联合国的最初目标和宗旨 目前的裁决进行审查，并在多大程度上，这些已经实现了划定。文件 机构支持的必要性以及通过K24机制继续提供支持的理由， 提供了